PRMT3 and metabolic dysfunction-associated steatotic liver disease: • In non-alcoholic fatty liver disease and atherosclerosis, SGC707 inhibits PRMT3 activity, reduces hepatic triglyceride accumulation, affects white adipocyte size, alters plasma bile acid levels and TGR5 activation.